Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05388708 · ClinicalTrials.gov registry record

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

A clinical trial of Acute Respiratory Distress Syndrome and Extracorporeal Membrane Oxygenation, sponsored by University of Michigan.

Recruiting
Registry status
550
Enrollment target
20
Study locations

NCT05388708 is a study of Acute Respiratory Distress Syndrome and Extracorporeal Membrane Oxygenation that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 550 participants, above the 350-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (57% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05388708, a study of Acute Respiratory Distress Syndrome and Extracorporeal Membrane Oxygenation, is actively recruiting participants, sponsored by University of Michigan.

RECRUITING
Registry status
550 participants
Enrollment target
20
Study locations

Study Summary

ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.

Interventions

  • DEVICE ECMO support
  • OTHER PROSpect protocolized therapies

Study Locations (20)

California

  • Loma Linda University Children's Hospital - Loma Linda
  • UCLA Mattel Children's Hospital - Los Angeles
  • Valley Children's Hospital - Madera
  • UCSF Benioff Children's Hospital Oakland - Oakland
  • Children's Hospital of Orange County - Orange
  • Lucile Packard Children's Hospital Stanford - Palo Alto
  • UCSF Benioff Children's Hospital - San Francisco - San Francisco

Florida

  • UF Health Shands Children's Hospital - Gainesville
  • Nicklaus Children's Hospital - Miami
  • Orlando Health Arnold Palmer Hospital for Children - Orlando
  • Nemours Children's Hospital, Florida - Orlando

Connecticut

  • Connecticut Children's Medical Center - Hartford
  • Yale New Haven Children's Hospital - New Haven

Alabama

  • Children's of Alabama - Birmingham

Arizona

  • Phoenix Children's Hospital - Phoenix

Arkansas

  • Arkansas Children's Hospital - Little Rock

Colorado

  • Children's Hospital Colorado - Aurora

Delaware

  • Nemours Children's Hospital, Delaware - Wilmington

Trial Details

FieldValue
Enrollment Target 550 participants
Start Date 2021-02-04
Est. Completion 2027-09-30

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT05388708

The ClinicalTrials.gov registry entry for NCT05388708 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 350-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (57% higher). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 2 interventions - of which ECMO support is the first listed.

NCT05388708 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05388708 about?

NCT05388708 is a clinical study titled "ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)". ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do...

What is the current status of trial NCT05388708?

This trial is currently recruiting. The enrollment target is 550 participants. The study started on 2021-02-04. Estimated completion is 2027-09-30.

What conditions does trial NCT05388708 study?

This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation.

What interventions are being tested in trial NCT05388708?

The interventions under investigation include: ECMO support (DEVICE), PROSpect protocolized therapies (OTHER).

Who is sponsoring clinical trial NCT05388708?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05388708 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Respiratory Distress Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.